Mediacast
- Peaks and Valleys
-
Dr. Mario Raviglione, director of the Stop TB Department at the World Health Organization, outlines the successes and set backs in the global effort to end tuberculosis.
- BIOspeak
-
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), discusses the most pressing policy challenges facing the industry today.
- A New Gold Standard
-
John Doyle, DrPH, practice leader for market access at Quintiles Consulting, discusses the concept of a health economic balance sheet and the need for evidence-based pricing for biopharmaceutical valuation.
- A Shot in the Arm
-
Darrick Carter, Ph.D., director of formulations for the Infectious Disease Research Institute, discusses the numerous public/private partnerships involved in developing more effective vaccines for neglected diseases.
- Informed Choices
-
Dr. Scott Gottlieb, resident fellow at the American Enterprise Institute, explains how pharma’s future is dependent on sound public policy.
- Untapped Potential
-
Dr. Alessio Fasano of the University of Maryland School of Medicine talks about current research into the treatment and management of celiac disease.
- Innovation Through Collaboration
-
Joseph McCracken, vice president of business development at Genentech, discusses his company’s partnering philosophy.
- Legislating Drug Safety
-
Doug Peddicord, Ph.D., executive director of the Association of Clinical Research Organizations, explains the myriad drug safety initiatives being debated in the United States Congress this year.
- A Sense of Urgency
-
Stephen Lewis, former UN Special Envoy for HIV/AIDS in Africa and current co-director of AIDS-Free World, offers impassioned advice on HIV/AIDS in Africa.
- Progress for Parkinson’s
-
Dr. William Marks, associate professor of neurology at the University of California – San Francisco, and Dr. Melanie Brandabur clinic director at the Parkinson’s Institute, explain the concepts behind gene therapy for the treatment of Parkinson’s disease and discuss some of the challenges in researching neurodegenerative disorders.
Web Exclusives
- Turning the Corner
-
After decades of neglect, leading to a rapid increase in incidence, tuberculosis started gaining attention from industrialized nations over the past 10 years. With this new focus, TB’s incidence has started to decrease—but barely.
- A Weighty Problem
-
As pharmaceutical companies search for a blockbuster fat-fighting drug, the biggest battle is against side effects.